Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Interleukin-1α neutralisation in patients with cancer.

Dinarello CA.

Lancet Oncol. 2014 May;15(6):552-3. doi: 10.1016/S1470-2045(14)70164-0. Epub 2014 Apr 17. No abstract available.

PMID:
24746840
2.

Progress in immunotherapy of cancer.

Rook AH, Raphael BA.

N Engl J Med. 2012 Sep 20;367(12):1168; author reply 1168. No abstract available.

PMID:
22992095
3.

[Value of monoclonal antibodies in the diagnosis and treatment of cancer].

Bron D.

Rev Med Brux. 1984 Feb;5(2):77-81. French. No abstract available.

PMID:
6718858
4.

[Targeting chemotherapy of cancer].

[No authors listed]

Nihon Gan Chiryo Gakkai Shi. 1988 Apr 20;23(4):970-82. Japanese. No abstract available.

PMID:
3204321
5.

Drug makers chase cancer stem cells.

Schmidt C.

Nat Biotechnol. 2008 Apr;26(4):366-7. doi: 10.1038/nbt0408-366c. No abstract available.

PMID:
18392005
6.

[Targeting therapy of cancer using monoclonal antibody-antitumor drug conjugate].

Yachi A, Imai K, Hirata H, Hishikawa N.

Nihon Rinsho. 1989 Jun;47(6):1391-5. Japanese. No abstract available.

PMID:
2475654
7.

[Utilization of antineoplastic agents in Sweden and Europe].

Wilking N, Jönsson B, Björn W.

Lakartidningen. 2010 Apr 21-27;107(16):1075-80. Review. Swedish. No abstract available.

PMID:
20476705
8.

Antibody-drug conjugates for cancer: poised to deliver?

Hughes B.

Nat Rev Drug Discov. 2010 Sep;9(9):665-7. doi: 10.1038/nrd3270. No abstract available.

PMID:
20811367
9.

The immune system in the fight against cancer.

[No authors listed]

Future Oncol. 2006 Feb;2(1):11. No abstract available.

PMID:
16634135
10.

Antibody-directed enzyme/prodrug therapy (ADEPT).

Bagshawe KD.

Biochem Soc Trans. 1990 Oct;18(5):750-2. Review. No abstract available.

PMID:
2083666
11.

Shortening the infusion time of anticancer drugs: who will benefit?

Margolin K, Gordon M.

J Clin Oncol. 2007 Jul 1;25(19):2642-3. No abstract available.

PMID:
17602068
12.

Keys to unlock cancer: targeted therapy.

Viele CS.

Oncol Nurs Forum. 2005 Sep 1;32(5):935-40. Review. No abstract available.

PMID:
16136192
13.

[Target-oriented tumor therapy -- proof of the principle].

Gastl G, Hiddemann W.

Dtsch Med Wochenschr. 2004 Oct 1;129(40):2093. German. No abstract available.

PMID:
15455299
14.

[Interleukin-21, new adjuvant for cancer therapy?].

Iannello A, Ahmad A.

Med Sci (Paris). 2009 Apr;25(4):341-3. doi: 10.1051/medsci/2009254341. French. No abstract available.

15.

A dynamic de-escalating dosing strategy to determine the optimal biological dose for antiangiogenic drugs.

Emmenegger U, Kerbel RS.

Clin Cancer Res. 2005 Nov 1;11(21):7589-92. No abstract available.

16.

[Metronomic chemotherapy. Should we change our thinking in the treatment of advanced tumors?].

Mauch C.

J Dtsch Dermatol Ges. 2005 Jan;3(1):3-4. German. No abstract available.

PMID:
16353744
17.

[Targeted drugs a chance for a better cure].

Bergh J, Jonsson B.

Lakartidningen. 2010 Apr 21-27;107(16):1071-4. Review. Swedish. No abstract available.

PMID:
20476704
18.

How can we improve antibody-based cancer therapy?

Yan L, Ehrlich PJ, Gibson R, Pickett C, Beckman RA.

MAbs. 2009 Jan-Feb;1(1):67-70.

19.

Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story?

Puglisi F, Piccart M.

Onkologie. 2005 Nov;28(11):547-9. No abstract available.

20.

[Bevacizumab].

Taéron C.

Rev Infirm. 2009 Jan-Feb;(147):46-8. French. No abstract available.

PMID:
19317091

Supplemental Content

Support Center